All Activity

Virginia marijuana regulators have launched a new online form and tip line through which people can report suspected violations of the state’s newly enacted law legalizing recreational cannabis sales. The legislation, passed as part of a large-scale budget bill, included a directive for the Virginia Cannabis Control Authority (CCA) to “establish, advertise, and administer a tip line, which may be accessed by phone and by internet, for members of the public to anonymously report concerns about, or suspected instances of, illicit retail marijuana practices in violation of this subtitle.” Now, CCA is following through with the form and the phone line. “Help us protect Virginia’s cannabis market,” CCA said. “Every report helps the Virginia Cannabis Control Authority investigate potential violations and protect public health and safety.” With the online form, people submitting reports can choose whether or not to remain anonymous and can choose from the following activity types: Counterfeit or unregistered products Diversion from licensed facility Illegal advertising Illegal cultivation or manufacturing Illegal delivery Illegal sale Sale to a minor Unlicensed sales Other The form also has fields to report the date, time and location of the allegedly illegal activity, and people also have the option to upload fils in support of their tips. People can also submit tips by calling 1-844-WEED-TIP (1-844-9333-847). CCA is also conducting a survey to gather input from the public and stakeholders as officials work to implement the state’s newly enacted law legalizing recreational cannabis sales. Meanwhile, current and former elected officials have clashed in recent days over allegations that lawmakers inadvertently erased all of the state’s cannabis-related penalties for a period of a year due to errors in enactment clauses in the recently passed marijuana legislation. Late last month, the Virginia Senate and House of Delegates adopted Gov. Abigail Spanberger’s (D) proposed amendments to budget legislation containing provisions to legalize recreational cannabis sales that they had given initial approval to previously. Because lawmakers accepted her suggested changes in full, the measure was immediately formally enacted into law and didn’t require any further action from the governor. Spanberger in May vetoed a previous measure to legalize recreational cannabis sales after lawmakers rejected her proposed amendments to the plan. She later negotiated with Sen. Lashrecse Aird (D) and Del. Paul Krizek (D), who sponsored the earlier measure, on a compromise deal that was included in the budget legislation that passed. The new plan differs significantly in several ways from the earlier legislation. For example, it sets the launch date for recreational marijuana sales at July 1, 2027, which is what Spanberger proposed in contrast to the January 1 date in what lawmakers had passed. It also sets the legal public marijuana possession and per-transaction purchase limit at 2 ounces, an increase from the current legal limit of one ounce. The legislation lawmakers passed earlier this year would have allowed adults to possess up to 2.5 ounces. The bill also cedes to Spanberger on language to increase a marijuana excise tax from 6 percent to 8 percent after two years of legal sales. By way of compromise, the new agreement will make public consumption of marijuana punishable by a civil penalty of $250—a significant increase from the $25 in current law but less harsh than the class 4 criminal misdemeanor the governor sought in her proposed changes to the previous bill. Lawmakers passed the initial cannabis sales bills in March, but the governor then suggested changes to the legalization proposal—including delaying the start date for sales by six months, increasing taxes and instituting new criminal penalties for cannabis consumers. The legislature in April declined to take up the amendments during a one-day reconvened session, however, effectively rejecting them. Spanberger then issued a veto. Spanberger said in June that she was having “really productive” and “incredible” conversations with lawmakers about crafting a compromise approach to legalizing adult-use cannabis sales, and Marijuana Moment previously reported on the ongoing talks. The governor, meanwhile, has tried to publicly explain her veto—including by saying it is her view that “taking a little bit longer” to launch the market is not something she sees as “negative” because it is more important to get the details right than to do it fast. A recent survey found that bipartisan majorities of Virginia voters wanted Spanberger to sign the cannabis legislation into law, and that they specifically disagreed with her desire to slow the launch timeline for legal sales. The governor recently acknowledged in a separate interview that “a lot of people are not pleased” with her veto of the cannabis legislation. “Friends and family are displeased as well,” she said. Spanberger has repeatedly responded to criticism of her cannabis amendments from the bill sponsors and advocates by saying the suggested changes came after she spoke to the leaders of other states that have already implemented adult-use marijuana markets. A spokesperson for Spanberger declined to name any other governors she talked to about cannabis in response to a question from Marijuana Moment, however. The governor separately sought to explain her veto in an earlier interview, reiterating that she supports launching a legal cannabis market but worried about what she called a “rushed timeline” and “far more stores across Virginia” than she thinks are appropriate. Personal marijuana possession and home cultivation of marijuana has been legal in Virginia since 2021, but then-Gov. Glenn Youngkin (R) twice vetoed bills to provide consumers with a way to legally purchase regulated adult-use cannabis. Here are the key details of the new cannabis plan in the budget and how it compares to legislation that Spanberger vetoed—SB 542 and HB 642—as well as her previously proposed amendments to those measures: Adults will be able to purchase up to 2 ounces of marijuana in a single transaction, or up to an equivalent amount of other cannabis products as determined by regulators. That will represent an increase from the limit in current law of 1 ounce. Lawmakers previously proposed setting the amount at 2.5 ounces and the governor only wanted 2 ounces. Legal sales can begin on July 1, 2027. Lawmakers previously set the date for January 1, 2027, but the governor wanted it pushed back to July 1. There will be an excise tax of 6 percent on cannabis sales as well as a 5.3 percent retail sales and use tax, and municipalities will be allowed to set an additional local tax of up to 3.5 percent. Starting on July 1, 2029, the state excise tax will increase to 8 percent, in line with the governor’s previously proposed amendments. Revenue will be distributed to the Cannabis Equity Reinvestment Fund, early childhood education, the Department of Behavioral & Developmental Health Services and public health initiatives. The earlier measure passed by lawmakers would have allocated specific percentages to each, but the new language doesn’t specify what portion of revenue will go to each program. The governor, in her amendments, wanted to put all revenue into the general fund while earmarking it “for purposes such as early childhood education, behavioral health, public health awareness, prevention, treatment, and recovery services, workforce development, reentry, indigent criminal defense, and targeted reinvestment in historically disadvantaged communities.” Her amendment also sought to eliminate support for the Cannabis Equity Reinvestment Fund. The Virginia Cannabis Control Authority will oversee licensing and regulation of the new industry, and will also take on oversight of hemp, which is currently under the Department of Agriculture and Consumer Services. The body will be governed by a five-member board of directors appointed by the governor, whereas the bill previously passed by lawmakers contemplated a seven-member body with four appointed by the governor, two appointed by the speaker of the House and one appointed by the Senate Rules Committee. The definition of what constitutes a legal hemp product will be narrowed by removing a provision from current law that allows those containing more than 2 milligrams of total THC per package if they also have a ratio of CBD to THC that is 25:1 or more. Up to 350 retail marijuana stores will be allowed to be licensed to operate across the state, the same number that lawmakers had approved and greater than the 200 the governor had proposed. Local governments will not be able to opt of allowing marijuana businesses to operate in their area. Delivery services will be allowed. Serving sizes will be capped at 10 milligrams THC, with no more than 100 mg THC per package. Public use of marijuana will be a civil violation punishable by a $250 fine. That is ten times more than the $25 fine under current law, but less harsh than the class 4 criminal misdemeanor crime the governor had proposed. Possession of cannabis by people under the age of 21 will be punishable by a $25 fine and mandatory participation in a substance abuse treatment or education program or both. The governor had suggested treating underage possession as a class 1 misdemeanor, punishable with a mandatory minimum fine of $500 or 50 hours of community service, as well as the suspension of drivers licenses for at least six months. Existing medical cannabis operators can enter the adult-use market if they pay a $10 million licensing conversion fee. Cannabis businesses will have to establish labor peace agreements with workers. A legislative commission will be directed to study adding on-site consumption licenses and microbusiness cannabis event permits that would allow licensees to conduct sales at venues like farmers markets or pop-up locations. That provision was also included in the earlier legislation lawmakers passed but was suggested for deletion by the governor. Meanwhile, the governor signed several other reform bills this session—including measures to provide resentencing relief for people with past cannabis convictions, protect the parental rights of marijuana consumers and allow patients to access medical cannabis in hospitals. The post Virginia Marijuana Officials Are Asking People To Report Violations Of The State’s New Legalization Law With A New Web Form And Tip Line appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The Department of War (DOW) has issued a memo to senior Pentagon leadership making clear that marijuana use by military service members and civilian employees of the department remains prohibited, even as the Trump administration is moving to federally reschedule cannabis. DOW “maintains a drug-free workplace to protect national security, public safety, and operational readiness,” the one-page document dated July 9 and obtained by Marijuana Moment says. Under an order issued by U.S. Acting Attorney General Todd Blanche in April, marijuana products regulated by a state medical cannabis license immediately moved from Schedule I of the Controlled Substances Act (CSA) to Schedule III, as did any marijuana products that are approved by the Food and Drug Administration (FDA). An ongoing administrative hearing is considering broader marijuana rescheduling. The new Pentagon memo, which has not previously been reported, seems to not recognize that medical cannabis rescheduling has already occurred, however, saying that “if implemented,” the reform “would not decriminalize marijuana under Federal law.” “Service members are reminded that the Uniform Code of Military Justice (UCMJ) prohibits certain actions, including the wrongful use, possession, manufacture, or distribution of marijuana, and attempts to commit such acts,” Anthony J. Tata, the under secretary of war for personnel and readiness, wrote. “These offenses remain punishable under the UCMJ, even if a State or local jurisdiction legalizes the use of recreational marijuana or authorizes the sale of marijuana, including medical marijuana, at State dispensaries.” Lynn Wagner, the executive director of DOW’s Office of Drug Demand Reduction, is listed as a point of contact on the memo, though she did not immediately respond to Marijuana Moment’s request to verify the document, nor did the Pentagon’s press office. “Service members who violate the UCMJ may be held appropriately accountable, including through judicial, nonjudicial, or administrative action,” Tata wrote in the memo, adding that civilian employees of DOW are subject to restrictions of the department’s Drug-Free Workplace Program. “These prohibitions do not apply to formulations approved as drugs by the FDA with a valid prescription for a legitimate medical purpose,” he concluded. The Congressional Research Service, however, published a report on the cannabis rescheduling move explaining that certified patients who possess medical marijuana from state-licensed dispensaries now have certain protections under Schedule III. “The order appears to authorize end users to possess marijuana for medical use without a CSA-compliant prescription,” it says. The Army, meanwhile, enacted a new policy in April making it so recruits will no longer need to obtain a waiver to enlist if they have a single conviction for possessing marijuana or drug paraphernalia on their records. That said, military branches have regularly warned service members about the consequences of using marijuana or even federally legal hemp-derived products. In May, for example, the Army published a post reminding soldiers of its “zero-tolerance” policy for all forms of cannabis and its derivatives—including hair care products and lotions made from hemp. Last year, a memo to Air Force personnel in Massachusetts warned that not only marijuana but also hemp-derived cannabinoids, including CBD and delta-8 THC, are prohibited on military bases and related properties. In 2022, the Air Force expressed concern that even using CBD-infused hand sanitizer or hemp granola could inadvertently compromise “military readiness.” DOD broadly reaffirmed that CBD is off limits to service members in notices published in 2020. The Navy, for its part, issued an initial notice in 2018 informing ranks that they’re barred from using CBD and hemp products no matter their legality. Then in 2020 it released an update explaining why it enacted the rule change. The Coast Guard said in 2019 that sailors can’t use marijuana or visit state-legal dispensaries. Read the full DOW marijuana memo below: The post Military Warns That Trump’s Marijuana Rescheduling Move Doesn’t Allow Use By Service Members appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

HHS/VA psychedelics partnership; ID medical marijuana push fails; CA data: Local bans boost illicit market; Study: Cannabis-infused tea & happiness Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Hold on, just one second before you read today’s news. Have you thought about giving some financial support to Marijuana Moment? If so, today would be a great day to contribute. We’re planning our reporting for the coming months and it would really help to know what kind of support we can count on. Check us out on Patreon and sign up to give $25/month today: https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW The Idaho Secretary of State’s Office announced that medical cannabis activists failed to submit enough valid signatures to qualify a legalization initiative for the November ballot. The Department of Health and Human Services and Department of Veterans Affairs launched a new effort to partner on psychedelic medicine development as other federal agencies also announced support for research on ibogaine’s therapeutic value. A new Congressional Research Service report lays out lawmakers’ options for how to address a federal law barring users of marijuana and other illegal drugs from possessing guns following a Supreme Court ruling that upheld cannabis consumers’ Second Amendment rights. “Congress might opt to amend the law to more narrowly capture only those individuals who may, because of their use or the nature of the drug involved, present a danger to themselves or others.” New data released by the California Department of Cannabis Control reveals that 97 percent of marijuana seized in unincorporated areas of the state came from counties that continue to ban licensed growers. “When local governments deny consumers access to licensed retailers, the illicit market and organized crime benefit, while public health and safety is harmed.” A new study found that drinking marijuana-infused tea leads to a “statistically significant increase in happiness levels” and improvements in sleep—without any negative reported side effects. “Cannabis-infused tea enhanced the state of happiness without reported side effects. Therefore, this prototype tea could be consumed at the optimum dose to maintain health and well-being.” More Maryland social equity marijuana dispensaries are starting to open this year after a slow start to market participation by people who come from communities—or who attended schools in parts of the state—that were disproportionately affected by the war on drugs. / FEDERAL Rep. Kevin Mullin (D-CA) filed a bill to ban retail and online sales of nitrous oxide products to consumers. The House bill to federally legalize marijuana got one new cosponsor for a total of 74. The House bill to create a cannabis-focused scholarship program got two new cosponsors for a total of three. / STATES Ohio Libertarian gubernatorial candidate Don Kissick said he supports lowering marijuana taxes. Oklahoma’s attorney general touted enforcement actions against medical cannabis dispensaries suspected of illegal activity. A Pennsylvania representative celebrated the lack of marijuana legalization language in budget legislation, saying that “aside from being federally illegal, we heard horror stories from other states saying much of the revenue brought in by legalization was canceled out by an increase in funding needed for Medicaid and mental health services.” New York regulators published guidance about including cannabis brand information in the state’s track-and-trace system. Washington, D.C. regulators upheld the rescission of a medical cannabis retailer application. Maine regulators sent a warning about a scam involving phone calls from people purporting to represent the state Office of Cannabis Policy. Virginia regulators published an overview of the Cannabis Public Health Advisory Council. California regulators sent updates on various cannabis issues. The New Jersey Cannabis Regulatory Commission will meet on Thursday. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / INTERNATIONAL Thailand’s deputy interior minister launched a crackdown on illegal cannabis sales. Namibia’s High Court rejected a case seeking to overturn marijuana prohibition. / SCIENCE & HEALTH A study found that treatment with cannabis-based medicinal products “was associated with improvements in [health-related quality of life], anxiety, and sleep outcomes in autistic patients over an 18-month period.” A case report “highlights a potential adjunctive role for cannabidiol in refractory [paroxysmal sympathetic hyperactivity] following severe” traumatic brain injury. / ADVOCACY, OPINION & ANALYSIS The Josh Kesselman Foundation for Making the World a Better Place is a new foundation focused on supporting cannabis reform and other issues. / BUSINESS The founder of Gold Flora and other cannabis companies is facing federal charges of illegally obtaining pandemic-related loans. A lawsuit that former Arkansas Gov. Mike Huckabee (R) filed against Meta Platforms, Inc. over alleged scam ads that use his name, image or likeness to sell CBD products was revived by the U.S. Court of Appeals for the Third Circuit. / CULTURE Sacha Baron Cohen pretended to be selling marijuana as his character Ali G during an appearance at the Wimbledon tennis tournament. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post Congress’s options for addressing cannabis user gun ban (Newsletter: July 15, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A balanced lifestyle, regular physical activity, and proper rest are the foundation of lasting health. I also came across best sex stamina pills, which are formulated with herbal ingredients that may support vitality, confidence, and overall stamina as part of a healthy daily routine.

Positive site, where did u come up with the information on this posting?I have read a few of the articles on your website now, and I really like your style. Thanks a million and please keep up the effective work. situs toto

Why settle for less when Gurgaon Escorts Service offers the best in the industry? Their team is well-trained to handle every detail of your appointment, from initial inquiry to the final meeting. Using a professional Escorts Service Gurgaon ensures that you stay safe and comfortable, allowing you to relax and enjoy the company of a stunning woman tonight.

I am impressed. I don't think Ive met anyone who knows as much about this subject as you do. You are truly well informed and very intelligent. You wrote something that people could understand and made the subject intriguing for everyone. Really, great blog you have got here. 인디고 게임

In college, facing a research paper on sustainable urban planning, I felt like I was climbing a steep Slope. The topic was vast, sources conflicting, and my ideas unformed. I eventually focused on community gardens, finding my voice in their connection to local food systems.

About 97 percent of marijuana seized by California officials in unincorporated areas of the state came from counties that continue to ban licensed growers, new data from the Department of Cannabis Control (DCC) reveals. That shows how local governments that have refused to get on board with California’s legalization law that voters approved 10 years ago “benefit” the illicit market, the state’s top cannabis regulator told State Affairs, which obtained and first reported on the data. DCC has repeatedly argued that the current system of patchwork regulations—where localities are able to opt-in or opt-out of allowing certain types of licensed marijuana businesses from operating in their area—is a key factor keeping the state’s illegal cannabis trade alive. It creates barriers to access for adult consumers, while allowing unlicensed operators to function in a policy vacuum. To combat the problem, the state established the Unified Cannabis Enforcement Taskforce (UCETF) in 2022 to coordinate multi-agency enforcement action against illicit growers, manufacturers and sellers. Through that work, DCC has been able to put the local control issue into perspective. According to data on enforcement activity spanning October 2022 to August 2025, the department found that 96.6 percent of illicit marijuana seized by UCETF in unincorporated areas of the state was discovered in eight counties—almost all of which maintain local bans on licensed marijuana cultivators. DCC Director Clint Kellum said that “cannabis is used in every community, regardless of local rules,” and while localities can ban licensed shops, “they cannot eliminate consumer demand.” “When local governments deny consumers access to licensed retailers, the illicit market and organized crime benefit, while public health and safety is harmed,” he told State Affairs. Kellum added that the department “will continue applying pressure to illegal operators, particularly when the activity involves organized crime, unlawful transportation and distribution, illegal manufacturing, diversion, threats to the licensed market, environmental harm, labor exploitation or conduct that crosses jurisdictional lines.” DCC released the county-level data days after Gov. Gavin Newsom (D) touted the state’s work seizing 63,000 pounds of illicit cannabis valued at more than $104 million, while destroying more than 89,000 cannabis plants, from April to June. All told, the multi-agency task force has seized over 841,000 pounds (or 420 tons, as the governor’s office went out of its way to note in a press release) since its establishment four years ago. “Disrupting the illegal cannabis market is about more than seizing unlicensed products—it’s about taking on criminal networks, removing illegal firearms out of the hands of dangerous individuals, and stopping activity that threatens public safety,” the governor said. “Through strong multiagency collaboration, California is making clear: if you threaten our communities, we will act.” Meanwhile, Newsom is term-limited, but California’s two major party general election gubernatorial candidates both support legalization. Republican Steve Hilton, who is endorsed by President Donald Trump, recently told Marijuana Moment that taxes and regulations on cannabis are “too high.” Not all California Republicans are on board with the reform, however. The vice chair of the state Senate Budget Committee has floated the idea of putting a new initiative on the state ballot to “reverse” Proposition 64, for example, arguing that voters were misled and voicing concerns about the health impacts of marijuana use. “We have seen significant negative consequences of this legalization, both here as well as in other states,” the senator, who was speaking at a hearing at which lawmakers approved a bill to legalize marijuana dispensary drive-thru windows in California, said. Democratic gubernatorial contender Xavier Becerra, who previously served in Congress and as California’s attorney general, meanwhile, facilitated a scientific review process during his time as health and human services secretary under the Biden administration that ultimately resulted in a recommendation to move cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA). — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Meanwhile, California regulators recently adopted emergency rules changes for the state’s marijuana licensing process that are intended to make it easier for businesses to qualify for benefits in line with the Trump administration’s recent decision to move ahead with federally rescheduling medical cannabis. They also launched a new AI tool to help businesses identify marijuana product packaging may appeal to kids in violation of state rules. Separately, Newsom recently took credit for helping to lead the push for the state to legalize marijuana and discussed his own limited experience with using cannabis. In October, however, the governor vetoed a bill that would have allowed certain marijuana microbusinesses to ship medical cannabis products directly to patients via common carriers like FedEx and UPS, stating that the proposal “would be burdensome and overly complex to administer.” Newsom did sign a bill earlier that month aimed at streamlining research on marijuana and psychedelics. In September, the governor also signed a measure into law to put a pause on a recently enacted tax hike on marijuana products. Separately, the state attorney general says Indian tribes cannot independently engage in marijuana commerce with licensed cannabis businesses without first obtaining their own commercial license from state officials. California officials recently awarded nearly $30 million in grants for marijuana-focused academic research projects. Photo courtesy of Chris Wallis // Side Pocket Images. The post California’s Top Marijuana Regulator Says Local Bans ‘Benefit’ Illicit Market, With 97% Of Busts In Counties Without Legal Growers appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Idaho voters will not get a chance to decide on an initiative to legalize medical marijuana on the November ballot, state officials have determined. Activists with the Natural Medical Alliance of Idaho (NMAI) earlier this month announced that they had made a final submission of county-verified signatures for the cannabis measure—but the Secretary of State’s Office said on Tuesday that the “initiative did not qualify for the November ballot after failing to submit the required number of valid petition signatures, both in total number of signatures and required legislative districts.” To be certified for the ballot, the team needed to submit signatures from at least 6 percent of registered voters as of the state’s last general election, which currently amounts to 70,725. They also needed to meet that 6 percent threshold in at least 18 of the state’s 35 legislative districts. While the campaign submitted more than 150,000 total signatures in May, there were some recent indications that there could be an issue meeting the county-level requirement as well as potentially the statewide total. A judge ruled last month that signatures in Minidoka County were turned in too late to be counted. Separately, some petitions for the medical cannabis measure throughout the state were at risk of being thrown out due to the possibility they may have been collected by out-of-state circulators. Now those fears have come to fruition and the medical marijuana measure won’t get a chance to be enacted this year. NMAI said in a statement on Tuesday that organizers are “shocked that the initiative did not qualify for the ballot,” placing the blame for the failure to turn in enough valid signatures on the first petitioning contractor it engaged before switching to a different firm late in the drive. “NMAI organizers oversaw this effort actively and in good faith. As the campaign progressed, we saw signs that our original signature gathering vendor’s operation was disorganized, but when concerns were raised we were assured that legal requirements, including requirements related to reporting and residency, were being followed and signatures were on pace to surpass the threshold. It appears that our confidence was misplaced. The Secretary of State’s letter describes missed deadlines, circulator documentation and payment disclosures, and petition materials prepared incorrectly or submitted late. We take every claim in that letter seriously and no one wants answers more than we do. We believe every statement made in the letter originated with our initial vendor. None of our concerns extend to the second firm we brought in late in the drive, whose work was professional throughout. NMAI has zero tolerance for signature fraud or prohibited conduct and will cooperate fully with any review.” The campaign said it is now “examining every legal and procedural remedy available, and whatever comes next, the need remains.” “The demand Idahoans expressed through this campaign is not going away,” NMAI said. “Idahoans deserve the right to make their own healthcare decisions and a government that trusts them to do so.” Meanwhile, voters in November will see a different kind of cannabis proposal on the ballot: A constitutional amendment that the legislature approved to make it so only lawmakers could legalize marijuana or other controlled substances—preventing the reform from being enacted by voters via a future ballot initiative. While NMAI pursued ballot access for the legalization measure, Idaho lawmakers have also pushed back in other ways. Both the Senate and House of Representatives passed a resolution this session urging voters to “reject” the medical marijuana petition. The measure, sponsored by the Senate State Affairs Committee, claims that cannabis legalization in other states has led to a host of harms, including “increased cartel activity, development of black market marijuana production, human trafficking, and increased crime rates” as well as “increased rates of serious health issues,” environmental harms and “safety concerns on job sites.” It argues that the marijuana initiative would not only increase costs to the state but that its list of approved medical conditions is “so broad that almost anyone could qualify.” “The Idaho Medical Cannabis Act lacks safeguards to such an extent that it would effectively legalize widespread recreational use of marijuana,” the resolution claims. “The legalization of marijuana would have devastating impacts on Idaho children and their families… The Legislature urges the citizens of Idaho to reject any effort to bring the Idaho Medical Cannabis Act to the ballot.” A statement of purpose filed with the legislation says it “addresses the devastating impact that legalizing marijuana has had on other states” and “identifies the significant problems” with the ballot initiative. Contrary to the claims made about marijuana reform in the legislative resolution, advocates often point to data showing that legalizing and regulating cannabis diminishes the size of the illegal market and has not led to increases in youth use. Meanwhile, NMAI recently released an analysis showing that Idaho could see more than $100 million worth of medical marijuana sold on an annual basis and up to $28 million in new yearly revenue for state coffers if voters approved the legalization initiative. The Idaho Medical Cannabis Act, which NMAI unveiled last October, would provide patients with qualifying conditions access to marijuana from a limited number of dispensaries and provide a regulatory framework for the market. Here are the main provisions of the Idaho Medical Cannabis Act: Health practitioners would be able to recommend medical cannabis to patients with conditions that include, but are not limited to, cancer, anxiety and acute pain. Medical marijuana patients or their designated caregiver could purchase up to 113 grams of smokeable cannabis, or 20 grams of THC extract for vaping, per month. The state would be start by issuing three vertically integrated cannabis business licenses, after which point it could license up to six total. Marijuana would be reclassified under state law as a Schedule II, rather than Schedule I, controlled substance. State and local law enforcement would be barred from assisting in federal drug enforcement activities related to the state-legal cannabis program. There would be anti-discrimination protections for those who use or sell marijuana in compliance from state law, preventing adverse actions by employers, landlords and educational institutions. It does not appear that there would be any equity-centered reforms, nor would the initiative provide for a home grow option. The campaign in February also released the results of a statewide poll showing that 83 percent of likely voters back medical cannabis legalization, including 74 percent of Republicans, 95 percent of Democrats and 92 percent of independents. Asked how they would vote if the current medical cannabis legalization does appear on the November ballot, 76 percent of respondents said “yes.” Of that cohort, 50 percent said they would “definitively” vote yes, and just 21 percent said they’d vote “no.” After the medical cannabis initiative was unveiled last year, a separate campaign that launched in 2024, Kind Idaho, told supporters that it would be suspending its own signature gathering for a ballot initiative to legalize the personal possession and cultivation of marijuana by adults. Kind Idaho previously introduced medical marijuana ballot measures intended to go before voters in both the 2022 and 2024 elections, but the efforts proved unsuccessful. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Legislators separately held a hearing last year to discuss a bill to enact medical cannabis legalization legislatively, but there hasn’t been meaningful action on the issue in the months since. Idaho Gov. Brad Little (R) last year signed legislation setting a $300 mandatory minimum fine for marijuana possession. A prior version of the proposal, which did not pass, would have set a $420 mandatory minimum fine for possessing cannabis. The post Idaho Medical Marijuana Initiative Fails To Qualify For November Ballot After Campaign Falls Short In Signature Drive appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Drinking a cup of tea infused with marijuana before going to bed can lead to a better night’s sleep and an overall improved sense of happiness in life, according to a new study. “The results demonstrated a statistically significant increase in happiness levels between pre-experimental and post-experimental groups, indicating that cannabis-infused tea had a positive effect on participants’ well-being,” the study, published this month in the Journal of Health Science and Medical Research, found. Researchers with Rajamangala University of Technology Isan in Thailand separated 30 volunteers into three groups that received drip tea infused with 3 percent, 5 percent or 7 percent cannabis, weight by weight. The participants were instructed to steep marijuana leaves in hot water and then drink the infused tea 30 minutes before bedtime every day for a week. Their happiness levels were assessed with a 15-item questionnaire and a follow-up phone interview at the end of the trial. “The findings from this study support the potential application of cannabis-infused tea in improving happiness levels.” The groups that received the 5 and 7 percent by weight marijuana tea infusions reported improved sleep quality. The 7 percent cohort had the “highest level of happiness score,” the authors wrote, with that preparation found to be “the most suitable formula for increased happiness.” “It contributed to improvements in life satisfaction, self-esteem, the ability to confront and accept problems, the ability to regulate emotions, a sense of confidence, a sense of empathy for others, and a greater sense of security with family,” the study says. “Cannabis-infused tea enhanced the state of happiness without reported side effects,” the paper concludes. “Therefore, this prototype tea could be consumed at the optimum dose to maintain health and well-being.” “Cannabis-based tea products may be a promising avenue for healthcare research and therapeutic applications in treating neurodegenerative disorders.” The researchers cautioned, however, that it is possible that the effects of herbal substances in the tea itself, such as peppermint and stevia, could have contributed to changes in participants’ happiness levels—and that also said that future studies should examine the long-term efficacy and safety of drinking cannabis-infused tea. The new research adds to a body of prior studies that have found benefits of cannabis consumption for mood and wellness. A study of adults who drink cannabis-infused beverages that was published earlier this year, for example, found evidence of a “substitution effect,” with a significant majority of participants reporting reduced alcohol use after incorporating cannabinoid drinks into their routines. It also identified improvements in overall wellbeing and sleep, as well as reductions in pain, stress, depression and anxiety. A survey from the American Academy of Sleep Medicine found that about 2 in 3 Americans who use marijuana say it improves their sleep. Separate research involving more than 3,500 patients showed that using medical marijuana appears to help people reduce the use of medications, including sleeping aids. They also experience far fewer negative side effects after switching to cannabis from prescription drugs. The cannabis component CBD can ease symptoms of moderate to severe anxiety after a short duration of use, another recent study found. The post Drinking Marijuana-Infused Tea Boosts Happiness And Sleep Quality, Study Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Butuh teks kosong untuk keperluan copy-paste di media sosial, aplikasi perpesanan, atau pengujian sistem? Anda berada di tempat yang tepat. Layanan kami menyediakan karakter khusus yang tidak terlihat oleh mata manusia namun terbaca oleh sistem sebagai teks, memungkinkan Anda untuk mengirim pesan kosong, membuat nama profil yang tidak terlihat, atau memformat kolom input sesuai kebutuhan Anda. https://tekskosong.xyz/en/

“The sad part was people who were targeted when there was prohibition on cannabis, those same individuals were excluded from the cannabis industry.” By Will Hammann, Maryland Matters When Candice Peters opened Coastal Cure Cannabis in Delmar on June 1, it was the culmination of more than two years of hard work on a decade-old dream. And that’s a fast turnaround compared to many of her peers. Of the 83 “social equity” licenses for dispensaries that have been distributed by the state since 2023, only 17 are currently in operation, twice the number that were open at the start of this year as more and more finally get their businesses off the ground. In addition to the challenges faced by any wishful entrepreneur, license holders say they also struggle with unique zoning issues, limited investors and unwilling real estate partners as the still-pervasive stigma around their product hangs in the air. “It’s been a journey,” said Peters. “And there have been a lot of long nights, and longer days trying to jump…all of these hurdles.” Peters, a physician who had long been interested in medical use of cannabis, first sought a license after marijuana was legalized for medicinal use in Maryland more than 10 years ago. But she didn’t come away with one then. “There were no minorities, or very few minorities that got these licenses,” she said. “They were supposed to be a very blind application process. That turned out not to be true, which is how we end up here.” The Cannabis Reform Act, which made recreational sales legal in 2023, also created the Maryland Cannabis Administration and the Office of Social Equity. It created the social equity licenses, for new dispensaries, growers and processors who came from Maryland communities—or who attended schools in communities—disproportionately affected by the war on drugs. “The sad part was people who were targeted when there was prohibition on cannabis, those same individuals were excluded from the cannabis industry,” Peters said. “Multimillions of dollars have been made, and no one who was affected by it, decades ago, was able to really profit from that.” That was echoed by Malcolm Gillian, founder of the Maryland Coalition for Cannabis Equity, a trade association representing social equity licensees like Peters. “Cannabis should never have been illegal—the enormous impact and harm on folk in arrests and everything else—I definitely want to see that be corrected,” said Gillian, who said he is a few months away from opening his own dispensary. He said his coalition, made up mostly of self-financed entrepreneurs, works to “make sure social equity licensees have the right funding opportunities, and frankly, when they get to market, have a chance to compete,” Gillian said Maryland’s law, and the Cannabis Administration, have “created a very healthy, very robust, legal marketplace versus other states that are still challenged with killing the illegal markets.” Sales have increased each year since recreational cannabis was legalized in 2023, according to data from the Cannabis Administration, totaling $3.46 billion since then and hitting a monthly record in April of $105 million in combined medical and recreational sales. “The MCA remains committed to providing a safe, equitable and accessible medical and adult-use cannabis industry for qualifying patients and adult consumers,” the administration said in a statement. Most dispensaries in the state began as medicinal-use operations that converted their licenses to sell recreational cannabis as well. There are 99 non-social equity equity licensed dispensaries currently operating in the state, according to MCA data. Peters noted that part of regulating the industry has been ensuring that new businesses weren’t founded or swept up by larger investors with multiple locations, sometimes across multiple states. “The resources that these multistate operators have, I mean, they’re so far above what we have access to,” she said. “Not just financially but in who we know, who we can contact to get expedited services. “This round of licenses was critical to, not even evening the playing field, but at least allowing us to have a seat at the table,” Peters added. “If half those licenses are bought up by multistate operators, the other half of us would never be able to compete with those numbers.” Making sure that social equity licenses stay in local hands is just one of the challenges the new businesses have faced. Peters, Gillian and Frank Hayes, an owner of Crabtree Cannabis in Kensington, said the law requiring that 65 percent of equity is held by the qualified applicant can make it especially difficult for social equity licensees to raise capital. Hayes, who sits on the board of the Maryland Dispensary Association, has spent time lobbying to strike a balance between attracting investors and keeping ownership in the hands of the people the special licenses were meant for. “We’re very limited in terms of what we can do from a marketing and advertising perspective,” he said. “We’ve lobbied to try to loosen up some of those restrictions with pretty little success.” There are other challenges. Hayes and co-owner Felicia Covel Rami, owner of a catering business and Baltimore native who won a social equity license in the state’s lottery in 2024, were renovating a former bank to become their dispensary when the state ordered work halted after complaints from two nearby churches. State regulations prohibit dispensaries within 500 feet of places of worship. It turned out the churches themselves lacked permits, and they were forced to move. Months after filing a lawsuit, the order was lifted, and their renovation could continue. Hayes said just finding a location was a challenge, as many landlords or their major tenants are unwilling to share space with a cannabis dispensary, even if it complied with zoning laws. “I think there is still certainly a stigma associated with cannabis because it’s federally illegal,” said Hayes, whose dispensary opened April 14. “I think a lot of that stigma originates from the war on drugs, which in my opinion was pretty misguided on behalf of the federal government.” Acting Attorney General Todd Blanche in April reclassified medical cannabis from a Schedule I to a Schedule III drug. That put cannabis on the same level as pain medicine and ketamine, in the eyes of the federal government, instead of side by side with drugs like heroin and LSD. That’s progress, said Peters and Hayes, who hope to see more cannabis research now that the rescheduling opens the door. But the order also created an uneasy future for the recreational side of dispensaries, since the federal Drug Enforcement Administration (DEA) still considers recreational cannabis illegal. “If anything, this April decision has just created a lot of confusion,” Hayes said. “Some licensees have chosen to register and apply with the DEA, others have chosen not to, but I don’t think either camp has confidence [nor] clarity on the path forward.” He and Covel Rami decided to register after their suppliers said they planned to do so, since registered businesses can’t deal with unregistered partners. Peters was already registered because of her medical career. But she noted that the DEA is the same agency that led the war on drugs that inspired the social equity license program and, “Choosing to trust them now, even for good reason, does cause me to pause.” “To now include something that’s federally illegal, and submitting information to the DEA is a little frightening,” she said. Hayes and Gillian, both of whom previously worked in California’s cannabis industry, said high taxes there in the past on adult-use cannabis had allowed an illegal market to continue to flourish. That is not the case in Maryland, which charges a 12 percent sales tax on the use of recreational cannabis, they said, “There is no longer like a local weed guy [in Maryland], everyone just goes to the dispensary,” Gillian said. “It’s safe, it’s clean.” “We’re in a state that has supported us,” Peters said. “I think Maryland does want us to be successful, so I’m hoping that they will support us going forward and moving through this whole process.” As Peters moves forward, she said she hopes the unique perspective of social equity licensees can fulfill the program’s purpose. “We’re intentionally trying to hire returning citizens, we’re intentionally trying to hire people of the underserved communities, and we’re intentionally trying to get the products out to those people as well,” she said. “I think as we destigmatize this, we’re only going to get more people that are using cannabis in a safe way.” This story was first published by Maryland Matters. The post More Maryland Social Equity Marijuana Dispensaries Are Finally Starting To Open, Years After Market Launch appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Thank you very much for this useful article. I like it. แทงบอลสด

Congressional researchers are detailing options for how lawmakers could respond to a recent Supreme Court decision to uphold the gun rights of people who use marijuana. Last month, the nine justices unanimously ruled that the government’s efforts to criminalize possession of firearms for cannabis consumers through a statute known as 922(g)(3) is an unconstitutional violation of the Second Amendment. The court itself described its ruling as “narrow,” and the new Congressional Research Service (CRS) report on the issue said it “explicitly recognized room for legislative action in this area.” The court’s opinion in the case, U.S. vs. Hemani, does not address “efforts to ban addicts, or those presently intoxicated, from possessing a firearm,” the majority opinion says. “We do not address other prophylactic laws Congress might adopt after determining that users of a particular drug pose a special risk of misusing firearms.” “We do not even address whether the government could bring a prosecution under §922(g)(3) accompanied by individualized proof that the defendant’s use of marijuana (or any other drug) renders him a danger to himself or others,” it said. “Or proof that a certain drug always renders its users dangerous because of its potency or for some other reason.” The new CRS report says that “Congress may accept this invitation to amend § 922(g)(3) if it chooses.” “For example, Congress might opt to amend the law to more narrowly capture only those individuals who may, because of their use or the nature of the drug involved, present a danger to themselves or others,” it says. “Congress may be interested in modifying other categorical prohibitions in § 922(g) in light of the Court’s discussion of historical laws, particularly to the extent that the government may turn to these laws in future cases to defend the constitutionality of a modern firearms restriction.” The report from congressional researchers also says, however, that lawmakers may alternatively want to “allow lower courts to sort out any residual questions from Hemani,” including how to interpret whether language in the statute that bars people who are “addicted to” illegal drugs from possessing firearms is consistent with the Second Amendment. “A number of petitions for review raising Second Amendment issues have been filed with the Court,” CRS said. “Should the Court grant any such petitions, Congress may have more information to consider when determining whether and what adjustments to § 922(g) may be appropriate.” — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — The Supreme Court, for its part, has already started applying its finding in the case to those involving other cannabis consumers who were prosecuted for possessing firearms. A recent poll, meanwhile, found that most Americans support the Supreme Court’s decision on gun rights for cannabis consumers—including majorities across party lines. Also, a federal agency that regulates guns says it is planning to provide guidance in the wake of the court ruling on the Second Amendment rights of people who use marijuana. The Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) noted the court’s unanimous ruling in a social media post, saying it is “reviewing the decision and assessing its impact.” “Additional guidance will be provided soon,” the agency said. ATF is responsible for carrying out the federal law known as 922(g)(3) that prohibits people who illegally consume controlled substances from possessing or purchasing firearms and has now been partially struck down when it comes to cannabis consumers who otherwise show no signs of posing a threat of violence. The court, in the majority opinion, said that the broad ban and the government’s effort to defend it are “at odds with” the Trump administration’s move to federally reschedule cannabis. The government “asks us to conclude that anyone who regularly uses marijuana is categorically violent and dangerous without any further showing,” the opinion says. “All based on little more than its current say-so, one at odds with its own regulatory actions. And affording the government that kind of ‘broad power to designate any group as dangerous and thereby disqualify its members from having a gun’ would risk allowing it to ‘quickly swallow’ the Second Amendment.” ATF in May posted a proposed revised version of Form 4473, which must be filled out by anyone purchasing a gun from a federally licensed firearms dealer, to acknowledge the federally legal status of medical marijuana under the Trump administration’s recent move to reschedule the drug. The change is likely due to the fact that in April, Acting Attorney General Todd Blanche issued an order that immediately moved marijuana products regulated by a state medical cannabis license to Schedule III of the Controlled Substances Act (CSA), and similarly rescheduled marijuana products that are approved by the Food and Drug Administration (FDA). A hearing to consider broader cannabis rescheduling is scheduled for this month. Advocates expect that ATF will need to issue further changes to the gun purchase form in the wake of the court’s ruling in U.S. v. Hemani, the case it decided this month. ATF also moved earlier this year to loosen rules that bar people who consume marijuana and other illegal drugs from being able to lawfully purchase and possess guns by making it so fewer people would be affected. The interim final rule from ATF, which is currently open for public comment through June 30, seeks to update the definition of “unlawful user of or addicted to any controlled substance” under an existing policy that has been interpreted to deny Second Amendment rights to people who have used illegal substances a single time within the past year. The Supreme Court heard arguments in the Hemani case in March, with the Trump administration urging the justices to uphold the ban on gun possession by marijuana users. The federal government has consistently maintained its position that the law appropriately disarms marijuana users who, they claim, are uniquely dangerous. To meet a strict Supreme Court standard for firearm laws, the Department of Justice has also drawn sometimes eyebrow-raising comparisons between cannabis consumers and the mentally ill and habitual drunkards to establish a historical analogue that aligns with the country’s founding era. “Those laws, the government contends, demonstrate a tradition of firearm regulation consistent with its effort to disarm any regular user of any controlled substance without any further showing. But the government’s analogy fails under every measure it asks us to consider,” the court’s opinion said. “The historical laws on which it relies targeted different kinds of people, did so for different reasons, and operated in different ways. And faced with all these shortcomings in the government’s submission, we cannot say it has carried its conceded burden of showing its prosecution of Mr. Hemani complies with the Second Amendment.” Trump administration Solicitor General D. John Sauer, for his part, told the Supreme Court in a brief that people who use illegal drugs “pose a greater danger” than those who drink alcohol. In a separate filing for the case, the Justice Department also emphasized that “the question presented is the subject of a multi-sided and growing circuit conflict.” In asking the court to take up the dispute, the solicitor general also noted that the defendant is a joint American and Pakistani citizen with alleged ties to Iranian entities hostile to the U.S., putting him on the FBI’s radar. Meanwhile, the Biden administration was evidently concerned about potential legal liability in federal cases for people convicted of violating gun laws simply by being a cannabis consumer who possessed a firearm, documents obtained by Marijuana Moment show. The previously unpublished 2024 guidance from former President Joe Biden’s Justice Department generally cautioned U.S. attorneys to use discretion in prosecuting federal cannabis cases, particularly for offenses that qualified people for pardons during his term. But one section seems especially relevant as the Supreme Court takes on a case challenging the constitutionality of the current federal gun statute. In interviews with Marijuana Moment, several Republican senators shared their views on the federal ban on gun possession by people who use marijuana—with one saying that if alcohol drinkers can lawfully buy and use firearms, the same standard should apply to cannabis consumers. Sauer, the solicitor general, sent the justices a letter in April arguing that the Trump administration’s move to federally reschedule marijuana should not impact their decision in the Hemani case. The post Congressional Researchers Lay Out Lawmakers’ Options To Address Gun Ban For Marijuana Users Following Supreme Court Ruling appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Two Trump administration cabinet members have announced that their departments are launching a new partnership to collaborate on research and development of psychedelic medicines to treat people struggling with serious mental health conditions. The Department of Health and Human Services (HHS) and Department of Veterans Affairs (VA) signed a memorandum of understanding, unveiled on Monday, that comes months after President Donald Trump issued an executive order aimed at expanding and expediting research on the potential therapeutic benefits of psychedelics. “America owes every veteran the best care our nation can provide,” HHS Secretary Robert F. Kennedy, Jr. said in a press release. “We’re not going to wait while promising treatments sit on the sidelines. Thanks to President Trump’s leadership, HHS and the VA are working together to develop safe, FDA-approved innovations and transition them from research into care so veterans can access the treatments they deserve.” VA Secretary Doug Collins said that “President Trump opened up a world of possibility for treating veterans and others with mental health conditions, and VA is proud to be part of this important work.” “Today’s MOU ensures effective cooperation with HHS as we try to turn research into life-changing treatment,” he said. HISTORIC: Secretary Doug Collins and Secretary Robert F. Kennedy, Jr. have signed an MOU to improve cooperation on psychedelic drug trials between VA and HHS. Read: https://t.co/iSEZ0QtN5q pic.twitter.com/0OLQyHh4yu — Veterans Affairs (@DeptVetAffairs) July 13, 2026 Under the MOU, the two departments will coordinate workforce training, develop clinical protocols and support research and real-world evidence generation. The goal is to prepare VA’s healthcare system to be able to implement any psychedelic medicines that receive Food and Drug Administration (FDA) approval. The press release says HHS and VA will specifically collaborate under the five-year agreement by: Increasing participation in clinical research on promising rapid-acting mental health treatments for veterans Training therapists, nurses, physicians, and other clinicians to safely administer future FDA-approved rapid-acting psychiatric drug products Collecting and sharing real-world data on the safety, effectiveness, and costs of these treatments to improve patient care and inform future policy Coordinating research and sharing evidence as appropriate and consistent with legal authority that may help inform future FDA regulatory decisions and coverage policies Developing clinical guidance and educational resources to help providers — and ultimately patients — understand how approved treatments should be delivered safely and effectively A second MOU announced on Monday between VA and FDA is aimed at bolstering information-sharing and scientific collaboration to advance psychedelic medicine development. “Too many Americans and their families continue to be affected by substance use disorder and serious mental illness, and we have a responsibility to pursue every appropriate opportunity to advance new treatment options,” FDA Acting Commissioner Kyle Diamantas said. “This agreement strengthens collaboration between the FDA and the Department of Veterans Affairs, allowing us to better leverage clinical trial data, real-world evidence, and scientific expertise to help speed the development and review of promising therapies while maintaining our rigorous standards for safety and effectiveness. By working together, we can help deliver new hope to patients who urgently need better treatment options.” Proud to partner with @SecKennedy on accelerating psychedelic medical treatments for Veterans suffering from mental illness. Readhttps://t.co/sgeo7hUtvO pic.twitter.com/pgfGKVOD9l — VA Secretary Doug Collins (@SecVetAffairs) July 13, 2026 Meanwhile, the National Institute on Drug Abuse (NIDA) also announced that it is awarding $2.3 million to support an investigational new drug application for ibogaine. “There is preliminary evidence that psychedelic therapies can rewire the brain and produce rapid improvements for people with serious mental illness or substance use disorders,” National Institutes of Health Director Jay Bhattacharya said. “However, we still have much to learn about long-term benefits and risks, including the potential for misuse. This collaboration helps strengthen the scientific foundation and clinical readiness needed to support safe, effective, real-world implementation.” Additionally, the HHS Advanced Research Projects Agency for Health (ARPA-H) is making available separate funds to support research on ibogaine’s role in treating opioid use disorder. “Treatment for opioid use disorder has been stuck in an innovation rut for decades, and Americans are paying a heartbreaking price,” ARPA-H Director Alicia Jackson said. “ARPA-H is poised to take bold action and knock down barriers to exploring the therapeutic potential of ibogaine for this devastating condition.” Finally, the HHS Health Resources and Services Administration (HRSA) issued a request for information on how the healthcare system should prepare to implement psychedelic medicines. “HRSA is committed to ensuring that health professionals and community-based healthcare providers are prepared to safely and effectively deliver innovative therapies as new options become available for people living with serious mental illness,” HRSA Administrator Tom Engels said. “By seeking input from clinicians, health centers, behavioral health providers, rural health experts, researchers, and other stakeholders, HRSA will be better positioned to understand the workforce training, care delivery models, and operational considerations needed to support the safe implementation of potential FDA-approved psychedelic drug products in the future.” Separately on Monday, FDA issued finalized guidance to help researchers studying the therapeutic benefits of psychedelics navigate the “unique challenges” of such investigations. The agency also announced it will be holding a public hearing on psychedelic therapy issues in September. FDA is taking new steps to support the development of potential psychedelic drug therapies for serious mental health conditions. Today, FDA, issued final guidance for industry on clinical investigations of psychedelic drugs, announced a public hearing to gather stakeholder input… pic.twitter.com/Y102CzYiOi — U.S. FDA (@US_FDA) July 13, 2026 Previously, FDA and HHS in April announced steps that they say will help with “accelerating” therapeutic access to psychedelics for patients dealing with serious mental health conditions. In May, a bipartisan coalition of 32 members of Congress sent a letter urging FDA to expedite ongoing reviews of psychedelic therapies. This month, lawmakers filed a new bill that would require the Department of Defense (DOD) to evaluate how ongoing research on the therapeutic benefits of psilocybin could help members of the military. A separate recently introduced bipartisan measure is intended to codify Trump’s psychedelics executive order into law. A pending proposed amendment to the National Defense Authorization Act would extend a psychedelics research effort at DOD for an additional six years. Image courtesy of CostaPPR. The post Federal Health Officials And VA Launch Psychedelic Research Partnership appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

PA marijuana licensing bill; Congressional bill on cannabis/drug testing in hospitals advances; MA psychedelics vote; Hemp & marijuana op-ed Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Your good deed for the day: donate to an independent publisher like Marijuana Moment and ensure that as many voters as possible have access to the most in-depth cannabis reporting out there. Support our work at https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW The Food and Drug Administration published a finalized version of guidance aimed at helping researchers studying the therapeutic benefits of psychedelics navigate the “unique challenges” of such investigations—and has also scheduled a public hearing on the issue for September. The House Energy and Commerce Subcommittee on Health approved a bill to require the Department of Health and Human Services to study how prevalent drug testing for marijuana, fentanyl and other drugs is in hospital emergency departments. The Massachusetts House of Representatives passed an economic development bill that includes provisions to create a five-year pilot program allowing the use of psychedelics to treat mental health conditions. Pennsylvania representatives filed a bill to award medical marijuana licenses to small, diverse and disadvantaged businesses—with the sponsor saying that the diversity goal included in the program “has not been met due to multistate corporations dominating the Commonwealth’s medical cannabis industry.” Morgan Tweet of IND HEMP argues in a new Marijuana Moment op-ed that cannabis businesses should support a new proposal called the Goodness of Hemp Act that she says addresses the concerns of regulated operators “while creating a framework that prioritizes consumer protection, market accountability and long-term industry stability.” / FEDERAL The U.S. Embassy and Consulate in Thailand sent an alert about new customs policies related to cannabis in the country. Former Sen. Cory Gardner (R-CO) tweeted that the late Sen. Lindsey Graham (R-SC) once told him, “Sorry, Cory. I can’t help Colorado solve its marijuana problem. While y’all got potheads, I got Baptists.” / STATES Nebraska’s attorney general spoke about approval of medical cannabis regulations. A Pennsylvania senator said he doesn’t “currently have the votes to move” his marijuana legalization bill through the committee he chairs. Members of the Puerto Rico Senate Health Committee are inspecting medical cannabis businesses this week. A federal judge rejected hemp farmers’ request for more time to appeal dismissal of their lawsuit challenging Maryland product restrictions. Montana regulators adopted changes to rules on marijuana product recalls. New York regulators launched new resources to help young people and the adults they trust discuss cannabis. Missouri regulators published the latest issue of their marijuana podcast. Oregon regulators will consider a marijuana business stipulated settlement agreement on Thursday. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / INTERNATIONAL An Irish senator authored an op-ed about the need to decriminalize drugs. Ghana’s government is considering legalizing industrial hemp. / SCIENCE & HEALTH A study suggested that “cannabidiol may represent a promising complementary therapeutic strategy for reducing orofacial pain associated with temporomandibular disorders.” A review concluded that “CBD is useful for people with epilepsy that doesn’t respond to other treatments.” / ADVOCACY, OPINION & ANALYSIS A Concerned Women for America official authored an op-ed arguing that marijuana should remain in Schedule I. / BUSINESS Ascend Wellness Holdings, Inc. is asking shareholders to approve a reverse stock split in support of a plan to uplist on a major U.S. exchange. Tilray Brands, Inc. is launching medical cannabis products in Panama. Quest Diagnostics published an annual report indicating that positive hair drug tests for marijuana and other substances among the U.S. workforce have increased over the last five years. / CULTURE Wrestler Rob Van Dam said marijuana is a “gateway out” of heroin addiction. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: The post FDA’s new psychedelic guidance & hearing (Newsletter: July 14, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Compete against skilled players from around the world in 2v2.io and prove your abilities in fast-paced multiplayer team battles every day.

The software says stunning to read these sort of revealing and additionally completely unique articles or reviews upon your webpages. https://joker123-game.co/

Took me time to read all the comments, but I really enjoyed the article. It proved to be Very helpful to me and I am sure to all the commenters here! It’s always nice when you can not only be informed, but also entertained! slot 5k

I found that site very usefull and this survey is very cirious, I ' ve never seen a blog that demand a survey for this actions, very curious... bola online

Butuh teks kosong untuk keperluan copy-paste di media sosial, aplikasi perpesanan, atau pengujian sistem? Anda berada di tempat yang tepat. Layanan kami menyediakan karakter khusus yang tidak terlihat oleh mata manusia namun terbaca oleh sistem sebagai teks, memungkinkan Anda untuk mengirim pesan kosong, membuat nama profil yang tidak terlihat, atau memformat kolom input sesuai kebutuhan Anda.

The Food and Drug Administration (FDA) has issued finalized guidance to help researchers studying the therapeutic benefits of psychedelics navigate the “unique challenges” of such investigations. The agency also announced it will be holding a public hearing on psychedelic therapy issues in September. “In recent years, interest in the therapeutic potential of psychedelic drugs has been increasing,” the FDA document published on Monday says. “Drug development programs for psychedelic drugs are subject to the same regulations and same evidentiary standards for approval as other drug development programs,” the agency wrote. “However, designing clinical studies to evaluate the safety and effectiveness of these products presents a number of unique challenges.” Psychedelics can “cause intense perceptual disturbances and alterations in consciousness that can last for several hours or days,” and can “have both rapid-onset and long-term benefits after only one or a few doses,” FDA said. The guidance—titled “Psychedelic Drugs: Considerations for Clinical Investigations”—notes that psychedelics are an “an emerging area of drug development” and provides considerations that sponsors of research on substances like psilocybin, LSD and MDMA should take into account. Among other areas, FDA is providing recommendations on how psychedelic studies handle issues such as chemistry, manufacturing, abuse potential and clinical pharmacology. It notes that designing well-controlled studies on psychedelics can be particularly challenging due to the “often intense perceptual changes induced by the drugs.” “This increases the potential for bias due to functional unblinding of patients, therapists, monitors, or raters,” the FDA document says. “Functional unblinding can lead to expectation bias in the patients who experience perceptual disturbances, or in those who observe them, which may lead to an expectation that the participant will experience clinical benefit; alternatively, those who receive a placebo and do not experience or observe a perceptual change may expect that the participant will not benefit.” The final guidance builds on a draft version that FDA initially published in 2023 and comes months after President Donald Trump issued an executive order aimed at expanding and expediting research on the potential therapeutic benefits of psychedelics. The agency said it took into account comments received in response to the draft version, and it is also accepting additional public feedback on the final document, FDA said in a Federal Register notice. Meanwhile, FDA on Monday also announced that it will hold a public hearing on September 14 to “obtain feedback and perspectives on issues associated with the potential future therapeutic use of drug products containing a psychedelic drug substance in supervised and supportive settings.” “The hearing will be conducted by a presiding officer, who will be accompanied by FDA panelists, including subject matter experts from the Center for Drug Evaluation and Research, as well as federal partner panelists,” the agency said in a Federal Register notice about the hearing. FDA is inviting interested parties to apply to present about specific topics at the hearing, but it also made clear it is not inviting commentary about certain matters. “FDA and our federal partners are interested in public input on the potential future therapeutic use of psychedelic drugs in supervised and supportive settings, including the following topics: (1) provider training and credentialing, (2) promotion of patient safety, (3) considerations for access, and (4) best practices for data collection and standardization,” it said. “FDA is not seeking comment on the following topics: (1) the safety or effectiveness of any particular drug product, or the merits of any pending or anticipated application before the Agency; (2) the scheduling status of any substance under the Controlled Substances Act, which is addressed through separate statutory processes; (3) the legalization or decriminalization of psychedelic substances, or the merits of state or local programs authorizing their use, although FDA welcomes input on data collection from such programs as described above; (4) religious, ceremonial, or personal (non-medical) use of psychedelic substances; or (5) individual disputes, enforcement matters, or complaints regarding specific practitioners or entities. Comments and presentations addressing these topics may not be considered.” FDA and the Department of Health and Human Services (HHS) in April announced steps that they say will help with “accelerating” therapeutic access to psychedelics for patients dealing with serious mental health conditions. In May, a bipartisan coalition of 32 members of Congress sent a letter urging FDA to expedite ongoing reviews of psychedelic therapies. This month, lawmakers filed a new bill that would require the Department of Defense (DOD) to evaluate how ongoing research on the therapeutic benefits of psilocybin could help members of the military. A separate recently introduced bipartisan measure is intended to codify Trump’s psychedelics executive order into law. A pending proposed amendment to the National Defense Authorization Act would extend a psychedelics research effort at DOD for an additional six years. Photo elements courtesy of carlosemmaskype and Apollo. The post FDA Finalizes Guidance On ‘Unique Challenges’ Of Psychedelic Research And Schedules Hearing On Therapeutic Uses appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I wanted to thank you for this great read!! I definitely enjoying every little bit of it I have you bookmarked to check out new stuff you post. Taruhan Bola Parlay I wanted to thank you for this great read!! I definitely enjoying every little bit of it I have you bookmarked to check out new stuff you post. Situs Taruhan Sports I wanted to thank you for this great read!! I definitely enjoying every little bit of it I have you bookmarked to check out new stuff you post. Domino88 Online I wanted to thank you for this great read!! I definitely enjoying every little bit of it I have you bookmarked to check out new stuff you post. Roulette Online I wanted to thank you for this great read!! I definitely enjoying every little bit of it I have you bookmarked to check out new stuff you post. Bandar Togel I wanted to thank you for this great read!! I definitely enjoying every little bit of it I have you bookmarked to check out new stuff you post. Ilucky88 Slot

“The Goodness of Hemp Act represents one of the most reasonable opportunities for compromise currently on the table.” By Morgan Tweet, IND HEMP Few industries have watched the rise of hemp-derived intoxicating products with more frustration than regulated cannabis. Yet one of the more interesting realities of this debate is that many cannabis operators have quietly entered the hemp market themselves. While publicly advocating for stricter restrictions on hemp-derived products, many have simultaneously launched hemp beverage brands, cannabinoid product lines or other investments tied to the category’s growth. That contradiction reveals something important: this debate is no longer about whether consumer demand exists. It does. The real question is what framework should govern it. One answer may be the Goodness of Hemp Act, a draft legislative framework developed by a coalition of hemp stakeholders and currently being shared with policymakers as Congress debates the future of hemp-derived cannabinoids. Though not yet formally introduced, the proposal is being considered by congressional offices both as a comprehensive framework and as a source of specific provisions that could strengthen existing legislative efforts—offering a path to better balance consumer protection, agricultural interests and long-term market stability. What we are suggesting is simple: regulated cannabis operators should be far more focused on how to responsibly regulate hemp than how to eliminate it. It’s not hard to understand why many in regulated cannabis businesses have placed a target on the hemp industry. After years of competing against products operating under a different set of rules, many operators view the approaching November 12 federal recriminalization of hemp THC products as an opportunity to finally reset the playing field. Some have spent years advocating for stronger restrictions on hemp-derived intoxicating products and may see recent legislative activity as evidence that those efforts are finally paying off. But there is an important question worth asking: What happens next? If the objective is simply to eliminate today’s hemp-derived marketplace, the industry may discover that prohibition solves less than expected. Some consumers will undoubtedly leave the category altogether. Many are not prepared to make the leap from a low-dose hemp beverage or wellness product to becoming a traditional cannabis consumer. The assumption that all of that demand simply migrates into regulated cannabis markets is unlikely to prove true. At the same time, history suggests that demand rarely disappears entirely. Poorly constructed policy often creates opportunities for underground operators willing to ignore the rules altogether. As legitimate businesses exit the market, bad actors are often left to fill the void with lower-quality, untested and potentially unsafe products. When those products reach consumers, they rarely distinguish between hemp, cannabis or cannabinoids. They simply conclude that the category itself cannot be trusted. Every negative consumer experience, every mislabeled product and every irresponsible operator damages confidence not only in hemp-derived products, but in cannabis products as well. The industry has spent years fighting stigma. It should be cautious about creating conditions that reinforce it. That is why efforts to modify or replace the hemp provisions included in last year’s congressional appropriations process should be a serious topic of interest for regulated cannabis operators. Congress has already signaled that the status quo is unlikely to continue. The question is no longer whether change is coming. The question is what replaces it. With Congress expected to revisit hemp policy later this year, the industry has an opportunity to move beyond temporary extensions and begin discussing what a durable national framework could actually look like. We believe the Goodness of Hemp Act represents one of the most reasonable opportunities for compromise currently on the table. Not because it ignores the concerns of regulated cannabis, but because it addresses them directly while creating a framework that prioritizes consumer protection, market accountability and long-term industry stability. First, the draft legislation would restrict inhalable hemp products, addressing one of the primary concerns raised by regulated cannabis operators. By reserving this category for regulated cannabis, the proposal creates greater certainty around market boundaries and reinforces the value of compliance within state-regulated programs. Inhalables remain the core dispensary product category, making this one of the most direct benefits for state-licensed operators. Second, the proposal would create clearer distinctions between hemp and cannabis based on THC concentration and intended use. The result is greater certainty about where hemp begins and ends, where cannabis begins and which regulatory framework applies. Third, and perhaps most importantly, the draft language creates a framework that prioritizes consumer protection and responsible market development over regulatory ambiguity. Instead of allowing bad actors to define the marketplace, it establishes guardrails that help legitimate businesses compete while giving consumers greater confidence in the products they purchase. Millions of consumers are being introduced to cannabinoids through low-dose beverages, wellness products and other regulated formats. Over time, that exposure can reduce stigma, improve understanding and help consumers become more comfortable navigating the broader cannabinoid marketplace. The counterintuitive reality is that the long-term success of regulated cannabis may depend less on eliminating hemp and more on helping shape the rules that govern it. Those rules should establish clear boundaries, reward compliance, protect consumers and build trust across the entire cannabinoid category. And that is where the Goodness of Hemp Act stands apart from many of the proposals currently being debated in Washington, D.C. Most focus on extending timelines, preserving the status quo or addressing a single segment of the market. The Goodness of Hemp Act takes a different approach. It seeks to create a durable framework that puts consumers first, supports farmers, establishes clear guardrails and provides a pathway for long-term market stability. The Goodness of Hemp Act is the product of extensive collaboration among stakeholders who recognized that the industry needs more than another extension, carveout or temporary fix. It represents one of the first serious attempts to develop a long-term framework that could provide greater clarity for regulated operators, stronger protections for consumers and new opportunities for farmers and rural communities. The conversation surrounding hemp has spent years focused on what one industry stands to lose. But the bigger question may be what the entire cannabinoid economy stands to gain from clearer rules and greater certainty. Regulated cannabis operators have legitimate concerns about today’s hemp marketplace. So do farmers, manufacturers, retailers and consumers. The debate has already moved beyond whether change is needed. The question now is what comes next. If lawmakers can create a system that protects consumers, establishes clear boundaries and rewards responsible businesses, both hemp and cannabis could emerge stronger. The future of cannabinoids will not be shaped by the industries that spend the most time fighting one another, but by those willing to do the difficult work of building rules that consumers can trust and legitimate businesses can operate under for years to come. Morgan Tweet is co-founder and CEO of IND HEMP and executive director of The Hemp Feed Coalition. She is helping lead a broad coalition of stakeholders working to align the interests of industrial hemp, consumer cannabinoid products and American agriculture around a comprehensive federal regulatory framework. Photo courtesy of Brendan Cleak. The post Hemp And Marijuana Businesses Should Unite Around A New Regulatory Framework That Protects Consumers And Supports Farmers (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net